Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01225315 · ClinicalTrials.gov registry record · Phase 2
Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma
A Phase 2 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 438
- Enrollment target
NCT01225315 is a Phase 2 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 438 participants.
The verdict
NCT01225315, a Phase 2 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 438 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of ACT-129968 in subjects with partly controlled asthma on reliever therapy only.
Interventions
- DRUG Placebo
- DRUG Setipiprant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2010-11-01 |
| Est. Completion | 2012-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01225315
The ClinicalTrials.gov registry entry for NCT01225315 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 438 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01225315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01225315 about?
NCT01225315 is a clinical study titled "Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma". This study will assess the efficacy and safety of ACT-129968 in subjects with partly controlled asthma on reliever therapy only.
What is the current status of trial NCT01225315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 438 participants. The study started on 2010-11-01. Estimated completion is 2012-02-01.
What interventions are being tested in trial NCT01225315?
The interventions under investigation include: Placebo (DRUG), Setipiprant (DRUG).
Who is sponsoring clinical trial NCT01225315?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.